Non-COVID-19 sepsis (Sepsis) has always been one of the common diseases in critically ill patients. The main treatment strategy is to kill pathogens and mitigate hyperinflammation. One study demonstrated that the supplementation with 576,000 IU cholecalciferol (vitamin D3) as a single dose in critically ill adults in the medical intensive care units (MICUs) can improve clinical outcomes, including acute physiology and chronic health evaluation II score (APACHE II), sequential organ failure assessment score (SOFA), and C-reactive protein (CRP).
It is a three-year, multi-center, prospective, parallel, double-blind, randomized controlled clinical trial for 240 eligible subjects, with administrations of vitamin D3 576,000 IU or placebo every 24 hours for 3 days (72 hours) within 96 hours after intensive care unit (ICU) admission.

开始日期2024-07-01

申办/合作机构

Chi Mei Medical Center

[+1]

NCT06069141 / RecruitingN/AIIT

Comparisons of Treatment Responses of Early Syphilis to 2.4 Milliunits (MU) Single-dose Benzathine Penicillin G With or Without Doxycycline in People Living With HIV

This randomized controlled superiority study will be conducted during 2023-2025. The eligible participants are adult people living with HIV (PLWH) who are newly diagnosed with early syphilis. Participants will be randomized in a 1:1 ratio to receive single-dose benzathine penicillin G (BPG) (2.4 MU intramuscularly once) plus doxycycline (100 mg orally twice daily for 7 days) or single-dose BPG. The primary outcome is serologic response, defined as a decline of rapid plasma reagin (RPR) titer by 4-fold or greater, at week 24 and week 48; and the secondary outcomes include microbiologic response of syphilis and bacterial sexually transmitted infections (STIs) assessed by nucleic-acid amplification test (NAAT) at week 4.

开始日期2024-01-01

申办/合作机构

National Taiwan University Hospital

[+6]

100 项与 Chi Mei Medical Center 相关的临床结果

登录后查看更多信息

0 项与 Chi Mei Medical Center 相关的专利（医药）

登录后查看更多信息

4,489

项与 Chi Mei Medical Center 相关的文献（医药）

2025-01-01·INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS

Acute myocardial infarction risk prediction in emergency chest pain patients: An external validation study

Article

作者: Nguyen, Phung-Anh ; Hsu, Jason C. ; Shih, Chun-Ming ; Chen, Chia-Jung ; Melisa, Septi ; Hsu, Min-Huei ; Hsu, Chien-Chin ; Hsu, Jason C ; Huang, Chien-Cheng ; Chang, Ching-Hung ; Yang, Hung-Yu ; Lin, Hung-Jung ; Liu, Ju-Chi ; Liu, Chung-Feng

BACKGROUND:

Chest pain is a common symptom that presents to the emergency department (ED), and its causes range from minor illnesses to serious diseases such as acute coronary syndrome. Accurate and timely diagnosis is essential for the efficient management and treatment of these patients.

OBJECTIVE:

This study aims to expand on a model previously developed by the Chi Mei Medical Group (CMMG) Emergency Department in 2020 to predict adverse cardiac events in patients with chest pain. The main goal is to evaluate the accuracy and generalizability of the model through external validation using data from other hospitals.

METHODS:

The initial model for this study was developed using data from three CMMG-affiliated hospitals in southern Taiwan. We utilized four supervised machine learning algorithms, namely random forest, logistic regression, support-vector clustering, and K-nearest neighbor, to predict the risk of acute myocardial infarction within a one month for emergency chest pain patients. The study used the model with the best area under the curve (AUC), recall and precision for external validation. The external validated data source was data collected from three hospitals associated with Taipei Medical University (TMU) in northern Taiwan.

RESULTS:

The original best model constructed by CMMG exhibited an AUC of 0.822, an accuracy of 0.740, a recall of 0.741, a precision of 0.566, a specificity of 0.740, and an NPV of 0.861. Subsequently, during the external validation phase, CMMG's top-performing model demonstrated acceptable validation result with TMU's data, achieving an AUC of 0.63, an accuracy of 0.661, a recall of 0.593, a precision of 0.243, a specificity of 0.691, and an NPV of 0.900. While the results indicate that the model's performance varied across different datasets and are not outstanding, the model is still acceptable for clinical application as a preliminary decision-support tool.

CONCLUSION:

This study highlights the importance of external validation to confirm the applicability of the previously developed predictive model in other hospital settings. Although the model shows potential in assessing chest pain patients in the ED, its broad clinical application requires further validation to ensure it can improve patient outcomes and optimize healthcare resource allocation.

2025-01-01·BRAIN BEHAVIOR AND IMMUNITY

Cumulative infection burden, cognitive impairment and dementia

Letter

作者: Li, Chen-Pi ; Chang, Hui-Chin ; Shen, Chun-Yu ; Gau, Shuo-Yan

2024-12-01·JOURNAL OF CLINICAL ANESTHESIA

Optimal dosage of ketamine as an adjuvant to regional anesthesia

Letter

作者: Hung, Kuo-Chuan ; Kao, Chia-Li ; Chen, I-Wen

项与 Chi Mei Medical Center 相关的新闻（医药）

2024-08-12

·drugs

Risks for Mortality, Adverse Heart, Kidney Events Lower With Tirzepatide for T2DM

MONDAY, Aug. 12, 2024 -- For patients with type 2 diabetes, treatment with tirzepatide (a dual glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptor agonist) is associated with lower risks for all-cause mortality and adverse cardiovascular and kidney events compared with glucagon-like peptide 1 receptor agonist treatment (GLP-1 RA), according to a study published online Aug. 12 in JAMA Network Open . Min-Hsiang Chuang, M.D., from the Chi Mei Medical Center in Tainan, Taiwan, and colleagues conducted a retrospective cohort study using U.S. Collaborative Network of TriNetX data from individuals with type 2 diabetes aged 18 years or older initiating tirzepatide or GLP-1 RA between June 1, 2022, and June 30, 2023. Data were included for 14,834 patients treated with tirzepatide and 125,474 treated with GLP-1 RA. The researchers found that 0.6 and 1.1 percent of patients in the tirzepatide and GLP-1 RA groups, respectively, died after a median follow-up of 10.5 months. Tirzepatide treatment was associated with a lower risk for all-cause mortality, major adverse cardiovascular events (MACEs), the composite of MACEs and all-cause mortality, kidney events, acute kidney injury, and major adverse kidney events (adjusted hazard ratios, 0.58, 0.80, 0.76, 0.52, 0.78, and 0.54, respectively). Compared with GLP-1 RA, treatment with tirzepatide was associated with greater decreases in glycated hemoglobin (treatment difference, −0.34 percentage points) and body weight (treatment difference, −2.9 kg). "These insights advocate for the integration of tirzepatide into therapeutic strategies for managing type 2 diabetes and highlight its potential to enhance current clinical practice," the authors write. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

临床结果AHA会议

100 项与 Chi Mei Medical Center 相关的药物交易

登录后查看更多信息

100 项与 Chi Mei Medical Center 相关的转化医学

登录后查看更多信息